Bioequivalence and pharmacokinetic prediction of oral marketed metformin extended-release tablets in Saudi Arabia
The convolution approach indicated that Glucophage<sup>®</sup> and Formit<sup>®</sup> have bioequivalent C<sub>max</sub> of 601 and 592 ng/ml, respectively. The two products had the same projected T<sub>max</sub> of 2.0 h and a modest AUC<sub>∞</sub> differential that did not violate the FDA's 80-125% limit.
Authors
- Ahmed A. Alomary (ORCID: https://orcid.org/0000-0002-4786-1380)
- Aiman Y. Alwadi (ORCID: https://orcid.org/0000-0003-2847-8391)
- Mohammed A. Amin (ORCID: https://orcid.org/0000-0001-5091-0641)
- Omar Z. Ameer (ORCID: https://orcid.org/0000-0002-9211-9791)
- Hamzah Maswadeh (ORCID: https://orcid.org/0000-0002-1218-2513)
- Ahmed A. H. Abdellatif (ORCID: https://orcid.org/0000-0002-3186-1896)
- Mohamed Abbas Ibrahim (ORCID: https://orcid.org/0000-0001-7535-5453)
- Abdullah S. Aljutyali
- Talal S. Alrashidi
Institutions
- Alfaisal University (SA)
- Qassim University (SA)
- King Saud University (SA)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1080/03639045.2025.2586793
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00